FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."
For the second time in three days the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's bloodthinner Effient and then this morning Merck announced the FDA is not ready to approve its cervical cancer vaccine Gardasil for older women.
The indictment of two Bear Stearns hedge fund managers for securities fraud is expected to be announced later on Thursday in connection with a fund tied to the subprime lending market, CNBC has learned.
Broadcom co-founder Henry T. Nicholas III was indicted Thursday on fraud, conspiracy and drug charges—including allegations he spiked the drinks of technology executives and customer representatives with ecstasy and maintained a warehouse for ecstasy, cocaine and methamphetamine.
You can get a steady diet of all things ASCO (American Society of Clinical Oncology) on CNBC and here at CNBC.com, so I'm gonna blog about something totally different. Well, it does have to do with cancer prevention. Specifically, staving off cervical cancer and/or the sexually transmitted disease known as HPV, which is the leading cause of cervical cancer.
A former Credit Suisse investment banker convicted of leaking inside information about pending mergers was sentenced to 10 years in prison by a federal judge Friday.
The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).
John F. Marshall spent decades teaching at business schools and watching his students parlay his lessons into fortunes on Wall Street. But when he and another professor reached for some of those riches themselves, events took a startling turn, the authorities say.
Appeals courts in New Jersey and Texas on Thursday scrapped verdicts against drug maker Merck stemming from some of the earliest trials involving its once popular painkiller Vioxx.
It just keeps getting worse. Pfizer, which is staring down the loss of a $13 billion-a-year drug (Lipitor) in the 2010-11 timeframe, needs the rest of its product portfolio and its drug development pipeline to be firing on all cylinders.
The White House said that President Bush would not veto a final bill from Congress that orders a halt to filling the Strategic Petroleum Reserve while oil prices are very high.
Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.
Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.
Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.
Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.
U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.
U.S. federal regulators will announce a settlement on Friday with former Fannie Mae executives over their alleged roles in a 2004 multibillion-dollar accounting scandal, a person familiar with the settlement said on Thursday.
This morning a little biotech company, Antigenics, announced that Russia has approved its kidney cancer drug Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.
U.S. regulators on Thursday said they are probing a possible connection between Merck's Singulair asthma drug and suicidal behavior.